These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 32929364)
21. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879 [TBL] [Abstract][Full Text] [Related]
22. NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation. Xiong M; Chen L; Zhou L; Ding Y; Kazobinka G; Chen Z; Hou T Theranostics; 2019; 9(24):7156-7167. PubMed ID: 31695759 [No Abstract] [Full Text] [Related]
23. MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147. Wang C; Xu C; Niu R; Hu G; Gu Z; Zhuang Z BMC Cancer; 2019 Jun; 19(1):577. PubMed ID: 31196010 [TBL] [Abstract][Full Text] [Related]
24. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. Tan S; Li H; Zhang W; Shao Y; Liu Y; Guan H; Wu J; Kang Y; Zhao J; Yu Q; Gu Y; Ding K; Zhang M; Qian W; Zhu Y; Cai H; Chen C; Lobie PE; Zhao X; Sun J; Zhu T Oncogene; 2018 Aug; 37(35):4887-4900. PubMed ID: 29780166 [TBL] [Abstract][Full Text] [Related]
25. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer. Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274 [TBL] [Abstract][Full Text] [Related]
26. Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer. Müller M; Güth U; Varga Z; Reeve K; Bjelic-Radisic V; Fleisch M; Tausch CJ; Elfgen C Anticancer Res; 2020 Apr; 40(4):2125-2131. PubMed ID: 32234905 [TBL] [Abstract][Full Text] [Related]
27. miR-4458 regulates cell proliferation and apoptosis through targeting SOCS1 in triple-negative breast cancer. Liu X; Wang J; Zhang G J Cell Biochem; 2019 Aug; 120(8):12943-12948. PubMed ID: 30873664 [TBL] [Abstract][Full Text] [Related]
28. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877 [TBL] [Abstract][Full Text] [Related]
29. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer. Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566 [TBL] [Abstract][Full Text] [Related]
30. Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients. Chu Y; Elrod N; Wang C; Li L; Chen T; Routh A; Xia Z; Li W; Wagner EJ; Ji P Oncogene; 2019 May; 38(21):4154-4168. PubMed ID: 30705404 [TBL] [Abstract][Full Text] [Related]
31. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333 [TBL] [Abstract][Full Text] [Related]
32. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926 [TBL] [Abstract][Full Text] [Related]
33. Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer. Ichinose J; Watanabe K; Sano A; Nagase T; Nakajima J; Fukayama M; Yatomi Y; Ohishi N; Takai D Cancer Sci; 2014 Sep; 105(9):1135-41. PubMed ID: 24975429 [TBL] [Abstract][Full Text] [Related]
34. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320 [TBL] [Abstract][Full Text] [Related]
35. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Franco HL; Nagari A; Malladi VS; Li W; Xi Y; Richardson D; Allton KL; Tanaka K; Li J; Murakami S; Keyomarsi K; Bedford MT; Shi X; Li W; Barton MC; Dent SYR; Kraus WL Genome Res; 2018 Feb; 28(2):159-170. PubMed ID: 29273624 [TBL] [Abstract][Full Text] [Related]
36. Large-Scale Alternative Polyadenylation-Wide Association Studies to Identify Putative Cancer Susceptibility Genes. Guo X; Ping J; Yang Y; Su X; Shu XO; Wen W; Chen Z; Zhang Y; Tao R; Jia G; He J; Cai Q; Zhang Q; Giles GG; Pearlman R; Rennert G; Vodicka P; Phipps A; Gruber SB; Casey G; Peters U; Long J; Lin W; Zheng W Cancer Res; 2024 Aug; 84(16):2707-2719. PubMed ID: 38759092 [TBL] [Abstract][Full Text] [Related]
37. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446 [TBL] [Abstract][Full Text] [Related]
38. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450 [TBL] [Abstract][Full Text] [Related]
39. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer. Ring A; Kaur P; Lang JE BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919 [TBL] [Abstract][Full Text] [Related]
40. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]